TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical history of physician-diagnosed ragweed- and grass pollen-induced rhinitis with or without conjunctivitis of \>1 year duration, with or without asthma~* Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Randomization Visits and must agree to remain abstinent or use (or have their partner use) any one of the acceptable methods of birth control within the projected duration of the study. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy, hormonal contraception.~Exclusion Criteria:~* Unstable, uncontrolled or severe asthma treated with long-acting beta agonists (LABAs) at the time of Screening~* Received immunosuppressive treatment within 3 months prior to Randomization (except steroids for allergic reactions other than asthma)~* History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, unknown cause, or inhalant allergen~* Diagnosis of eosinophilic esophagitis~* History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy~* Female and breastfeeding, pregnant or intending to become pregnant~* Received another form of allergen immunotherapy with the past month~* Previously exposed to MK-3641 (RAGWITEK®) or other sublingual ragweed immunotherapy~* Previously exposed to MK-7243 (GRASTEK®) or other sublingual grass immunotherapy~* Known history of allergy, hypersensitivity, or intolerance to the excipient ingredients of the study drug (except for Ambrosia artemisiifolia and/or Phleum pratense), or self-injectable epinephrine~* Unable to or will not comply with the use of self-injectable epinephrine~* Used an investigational drug within 30 days prior to Screening Visit, or plans to participate in another interventional clinical trial during the duration of this trial~* Family member of the investigational or sponsor staff involved in this trial~* Participating in this same trial at another investigational site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK-3641+ MK-7243 (Type: EXPERIMENTAL): Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 18 years of age~* Diagnosis of visual impairment exclusively due to ME secondary to CRVO~* BCVA score at Screening and Baseline between 73 and 19 letters Early Treatment Diabetic Retinopathy Study (ETDRS), inclusively (approximate Snellen chart equivalent of 20/40 and 20/400)~Exclusion Criteria:~* Uncontrolled blood pressure defined as systolic value of \> 160 mm Hg or diastolic value of \> 100 mm Hg at Screening or Baseline.~* Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye~* Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye~* Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline (eg, sorafenib \[Nexavar®\], sunitinib \[Sutent®\], bevacizumab \[Avastin®\])

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab arm (Type: EXPERIMENTAL): Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Clinical diagnoses of fibromyalgia, osteoarthritis, or rheumatoid arthritis -~Exclusion Criteria:~Congestive heart failure, stomach ulceration, unstable diabetes, and bipolar disorder~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient self-administration of cortisol (Type: EXPERIMENTAL): Intervention is patient self-administration of cortisol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is Caucasian.~* Current healthy smoker as judged by the Principal Investigator.~* Subject has smoked at least 10 commercially available non-menthol CCs per day (no brand restrictions) for the last 4 weeks.~* Subject has smoked for at least the last 3 consecutive years.~* Subject does not plan to quit smoking in the next 3 months.~Exclusion Criteria:~* As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).~* Subject has received medication within 14 days or within 5 half-lives of the medication (whichever is longer), which has an impact on cytochrome P450 1A2 (CYP1A2) or cytochrome P450 2A6 (CYP2A6) activity.~* Female subject is pregnant or breast feeding.~* Female subject does not agree to use an acceptable method of effective contraception.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Tobacco Heating System (THS 2.2) (Type: EXPERIMENTAL): Ad libitum use of THS 2.2 for 5 days in confinement
- Smoking abstinence (SA) (Type: SHAM_COMPARATOR): Abstinence from smoking for 5 days in confinement
- Conventional cigarette (CC) (Type: ACTIVE_COMPARATOR): Ad libitum use of subject's own preferred brand of CC for 5 days in confinement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cabbage Leaf Wraps in Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* osteoarthritis of the knee, Kellgren Lawrence stadium 2-3~* at least 50% of days with complaints~* initial pain intensity 45mm on a 100mm visual analoge scale~Exclusion Criteria:~* medication with corticoids or immunsupressing drugs~* secondary arthritis/arthrosis~* operation to the knee within 12 months prior~* injection within 4 weeks (cortison) or 6 months prior (hyaluronic acid)~* severe comorbidities (liver, kidney, asthma, psychiatric disorders etc.)~* participation in other studies~* pregnancy, breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabbage leaf wraps (Type: EXPERIMENTAL): Daily application of cabbage leaf wraps over night, 4 weeks application
- Diclofenac gel (Type: ACTIVE_COMPARATOR): daily application of diclofenac gel 4 weeks application
- Usual care (Type: NO_INTERVENTION): no specific intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eight Week Primaquine Regimen for the Treatment of Vivax Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with P. vivax parasitaemia~* Patients over 3 years~* Patients with G6PD deficiency to a safety trial~* Patients without G6PD deficiency to all other groups.~Exclusion Criteria:~* Children under the age of three~* Pregnant / breast feeding women~* Patients with severe clinical anaemia \[Hb\<7g/dl\]~* Patients with P. falciparum~* Patients unavailable for the duration of study.~* Patients who have taken antimalarial drugs in the 2 weeks prior to consultation.~* Patients with concomitant infections or whose general health is considered too poor.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Anti-coagulants in Fragile Patients With Percutaneous Endoscopic Gastrostomy and Atrial Fibrillation (ORIGAMI) Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with PEG and indication for treatment with long-term oral anticoagulant therapy~* Patients with Atrial Fibrillation~Exclusion Criteria:~* Children under 18 years old.~* Life expectancy \<30 days.~* Lack of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with PEG and oral anticoagulan treatment (Type: None): Patients with PEG and indication for treatment with long-term oral anticoagulant therapy due to non valvular atrial fibrillation (FNAV), according to the current guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of Enthesitis-related arthritis (ERA) or Juvenile psoriatic arthritis (JPsA) according to the International League of Associations for Rheumatology (ILAR) classification criteria of at least 6 months duration.~2. Active disease (ERA or JPsA) defined as having both:~   * at least 3 active joints~  * at least 1 site of active enthesitis at baseline or documented by history.~3. Inadequate response (at least 1 month) or intolerance to at least 1 nonsteroidal anti-inflammatory drugs(NSAID)~4. Inadequate response (at least 2 months) or intolerance to at least 1 Disease-modifying antirheumatic drugs (DMARD)~5. No concomitant use of second line agents such as disease-modifying and/or immunosuppressive drugs.~Exclusion Criteria:~1. Patients fulfilling any ILAR diagnostic JIA category other than ERA or JPsA.~2. Patients who have ever received biologic immunomodulating agents~3. Patients taking any non-biologic DMARD except for MTX (or sulfasalazine for ERA patients only).~4. Patients with active uncontrolled inflammatory bowel disease or active uncontrolled uveitis.~Other protocol-defined inclusion/exclusion criteria apply.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Period 2 - active (Type: EXPERIMENTAL): secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
- Treatment Period 2 - placebo (Type: PLACEBO_COMPARATOR): placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2-month old infants (55-89 days, inclusive)~Exclusion Criteria:~* Prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens)~* Previous ascertained or suspected disease caused by N. meningitidis~* History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;~* Any serious chronic or progressive disease~* Known or suspected impairment or alteration of the immune system

- Gender: ALL
- Minimum Age: 55 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- rMenB Lot1 (Type: EXPERIMENTAL): Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
- rMenB Lot2 (Type: EXPERIMENTAL): Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
- rMenB Lot3 (Type: EXPERIMENTAL): Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
- Routine (Type: ACTIVE_COMPARATOR): Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
- MenC + Routine (Type: ACTIVE_COMPARATOR): Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 2 and 14 years old~* Diagnosed with asthma, classified as mild persistent asthma according to Global Initiative Asthma Guidelines (GINA)~* Diagnosed with comorbid allergic rhinitis~Exclusion Criteria:~* Patients with suspected sinus infection~* Prior treatment with high dose inhaled corticosteroid requiring a dose higher than beclomethasone dipropionate 400 ug per day, or equivalent, other medications used in severe cases

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: EXPERIMENTAL): Participants were treated for 12 months after randomization: Participants 2 to 5 years of age took one 4 mg chewable tablet and 6 to 14 years of age took one 5 mg chewable tablet daily in the evening. If participants had exacerbated from mild to moderate within 12 weeks, inhaled corticosteroids (ICS) was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
- Inhaled Corticosteroids (ICS) (Type: ACTIVE_COMPARATOR): Participants were treated for 12 months after randomization: Each participant's physician selected the ICS agent, dose, and regimen. If participants had exacerbated from mild to moderate within 12 weeks, ICS was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents 11-18 years of age~* virgins (both male and female) with no intention of becoming sexually active during the study period~* who have been properly vaccinated against diphtheria, tetanus, pertussis~Exclusion Criteria:~* who had a previous confirmed or suspected disease caused by N. meningitidis;~* who have previously been immunized with a meningococcal vaccine~* who have received prior human papillomavirus (HPV) vaccine;~* who have any serious acute, chronic or progressive disease~* who have epilepsy, any progressive neurological disease or history of Guillain-Barre syndrome;~* who have a known or suspected impairment/alteration of immune function, either congenital or acquired~* who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;~* who have Down's syndrome or other known cytogenic disorders;

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- MenACWY + Tdap + HPV (Type: EXPERIMENTAL): Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6
- MenACWY →Tdap → HPV (Type: EXPERIMENTAL): Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8
- Tdap →MenACWY → HPV (Type: EXPERIMENTAL): Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy or for which standard therapy does not exist~* Patient has life expectancy of greater than 3 months~* Patient is able to swallow capsules~Exclusion Criteria:~* Patient has had chemotherapy, radiotherapy or biological therapy 2 weeks prior to taking study drug~* Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent~* Patient has active CNS metastases and/or carcinomatous meningitis~* Patient has primary central nervous system tumor~* Patient has a history of drug or alcohol abuse~* Patient has Hepatitis B or C~* Patient is HIV positive~* Patient has active infection or has received intravenous antibiotics, antiviral or antifungal agents 2 weeks before taking study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Arm A: Drug/Placebo
- B (Type: EXPERIMENTAL): Arm B: Placebo/Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Nalbuphine Versus Midazolam in Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: -~* Female gender .~* Age : 18 - 40 years old .~* Physical status : ASA II .~* Elective cesarean section~Exclusion Criteria:~* - Patient refusal .~* History of hypertension or cardiac diseases .~* Psychiatric disorders .~* Coagulopathy .~* Allergy to study drugs .~* Contraindication to spinal anesthesia .~* Failure of spinal anesthesia .

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- bupivacaine (Type: EXPERIMENTAL): 12.5 mg hyperbaric bupivacaine + 0.5 ml 0.9% normal saline .
- nalbuphine (Type: ACTIVE_COMPARATOR): 12.5 mg hyperbaric bupivacaine + 1 mg nalbuphine add in 0.5 ml 0.9% normal saline.
- midazolam (Type: ACTIVE_COMPARATOR): 12.5 mg hyperbaric bupivacaine + 2.5 mg midazolam .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete